Wilex reports Redectane data

Wilex AG (Xetra:WL6) reported final data from the Phase III REDECT trial to diagnose clear cell renal cell carcinoma (RCC). Redectane-aided positron emission tomography (PET) in combination with computed tomography (CT) met the co-primary specificity and sensitivity endpoints vs. CT alone (p<0.001 and p<=0.016, respectively). Wilex previously reported preliminary data from the trial showing that Redectane-aided PET plus CT met the specificity endpoint (p<0.001), but missed the sensitivity endpoint (p=0.052). Wilex said the preliminary analysis included data which had not undergone quality assurance reviews. The open-label, U.S. trial enrolled 226 pre-surgical patients with suspected renal cancer. ...